GSK Licenses Phase II Compounds from Exelixis
By Business Review Editor
Pharma Deals Review: Vol 2002 Issue 30 (Table of Contents)
Published: 2 Nov-2002
DOI: 10.3833/pdr.v2002.i30.976 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Exelixis signed a major licensing deal with GlaxoSmithKline for a series of Phase II compounds for the treatment of cardiovascular diseases, cancers and inflammatory diseases...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS